XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts Receivable Factoring
9 Months Ended
Sep. 30, 2022
Receivables [Abstract]  
Accounts Receivable Factoring Accounts Receivable Factoring
As a part of its working capital management, the Company sells certain receivables through a single third-party financial institution (the “Factor”) in a pan-European program. The amount sold varies each month based on the amount of underlying receivables and cash flow needs of the Company. These are permitted transactions under the Company’s credit agreements governing the ABL Facility and Term Loan Facility and the indentures governing the Senior Notes and Senior Secured Notes. The European factoring facility, which was renewed in March 2020, allows the Company to factor up to €120 million of its Euro-denominated accounts receivable, accelerating access to cash and reducing credit risk. The factoring facility expires in December 2023.
Costs incurred on the sale of receivables are recorded in other expense, net in the condensed consolidated statements of operations. The sale of receivables under this contract is considered an off-balance sheet arrangement to the Company and is accounted for as a true sale and is excluded from accounts receivable in the condensed consolidated balance sheet. Amounts outstanding under receivable transfer agreements entered into by various locations as of the period end were as follows:
September 30, 2022December 31, 2021
Off-balance sheet arrangements$49,155 $52,743 
Accounts receivable factored and related costs throughout the period were as follows:
Off-Balance Sheet Arrangements
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Accounts receivable factored$89,263 $68,897 $262,145 $286,214 
Costs156 117 395 421 
As of September 30, 2022 and December 31, 2021, cash collections on behalf of the Factor that have yet to be remitted were $5,216 and $673, respectively, and are reflected in other current assets as restricted cash in the condensed consolidated balance sheet.